Takashi Nakada

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1K citations · Full text

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai et al. · Clinical Cancer Research · 2019 · 164 citations

Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads

Takashi Nakada, Takeshi Masuda, Hiroyuki Naito et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 152 citations

Medicine, Radiation Oncology, Antibody Engineering +1

Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology

Yusuke Ogitani, Yuki Abe, Takuma Iguchi et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 50 citations

Wide Application, Medicinal Chemistry, Drug Targeting +12

Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody–Drug Conjugate

Kenji Iida, Amr H. Abdelhamid Ahmed, Akiko Kawano Nagatsuma et al. · Cancer Discovery · 2021 · 45 citations